A Phase 2 interventional study of anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration and Standard of Care Blood Pressure Management with Antihypertensives in Ischemic Stroke and Transient Ischemic Attack, sponsored by University College Dublin. Recruiting at 1 site in Ireland. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-07-11.
Sponsored by University College Dublin · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Ischemic Stroke with a site in Ireland — 3 open to participants now, 3 under way, none of them phase 3. Ischemic Stroke · Ireland.
Among the 10 studies in Ischemic Stroke with a site in Ireland, this one is one of 2 that started in 2024, is one of 2 in phase 2, and was the 7th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →3 of the 10 studies in Ischemic Stroke with a site in Ireland are open now. Recruiting first, the newest first:
Neuravi Limited · Sites in Ireland, Belgium, France and 1 more country
Ages 18–90
University College Dublin · Sites in Ireland
Ages 18–90
A study can be open while its sites in Ireland have not opened yet or have stopped. Only those recruiting at a site in Ireland →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 142 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 249 across the 8 interventional studies, 254 across the 2 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 8 most frequent:
University College Dublin is the lead sponsor of 114 studies on the registry; 33 are open to participants now.
University College Dublin has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
1 of the studies in Ischemic Stroke with a site in Ireland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07367100Neuravi LimitedA Pivotal Study Evaluating Safety and Effectiveness of Adaptative Tip Catheter in Patients With Acute Ischemic Stroke | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Ischemic Stroke with a site in Ireland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Stroke is the third most common cause of death worldwide and the leading cause of disability. High blood pressure is an important risk factor for stroke. Lowering a person's blood pressure reduces the risk of future stroke or heart attack, and current guidelines recommend treatment to a target of \<130mmHg for secondary prevention.
Home blood pressure measurement and telemonitoring are acceptable to patients, but there is uncertainty over the use of out of office blood pressure measurements in stroke patients in guidelines.
This is a study designed to establish the feasibility of a larger clinical trial, comparing home blood pressure monitoring, telemonitoring and medication titration with standard care. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.
Background:
Stroke is the third leading cause of global death, the leading cause of acquired disability and contributes substantially to dementia, cognitive decline, and healthcare costs. Global epidemiological studies such as INTERSTROKE and the Global Burden of Disease study estimated that hypertension is the leading modifiable risk factor for stroke, with a population attributable risk of approximately 50%. Recurrent vascular events (stroke, coronary events, vascular death) cause significant morbidity in ischaemic stroke survivors, affecting approximately 30% at 5 years.
High rates of failure to achieve guideline BP targets (\<130mmHg) are reported in clinical practice for patients following ischaemic stroke or TIA. Home blood pressure measurement and telemonitoring is recognised as acceptable to patients from previous studies, and some trials have noted a significant reduction in BP at 12 months. The latest ESO guidelines note continued uncertainty over the use of out-of-office blood pressure measurements for adult patients with ischaemic stroke or TIA due to insufficient data.
This trial will recruit patients with recent stroke/TIA events with systolic BP ≥140 mmHg and randomise them to standard of care or home BP monitoring with telemonitoring and medication titration. The study hypothesis is that home BP measurement and telemonitoring with medication titration may lead to improved BP control compared to standard of care clinical practice.
Aim:
The aim is to conduct an initial pilot randomised trial in Ireland and European centres involved in the European Stroke Organisation Trials Alliance. This feasibility study will assess key design aspects and establish trial governance, data management, and procedures in preparation for a larger definitive trial.
Methods:
Design: Prospective, open-label, blinded endpoint assessed (PROBE) randomised, parallel group pilot/feasibility clinical trial, comparing BP patient self-measurement and telemonitoring with office-based monitoring (standard of care) for improved BP control after ischaemic stroke/TIA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Medication titration to guideline SBP \<130mmHg
Other: anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration
Standard of Care Management by GP/physician to SBP \<130mmHg by current European Stroke Organisation, American Stroke Association and UK NICE guidelines
Other: Standard of Care Blood Pressure Management with Antihypertensives
A medication algorithm based on the SPRINT trial protocol will be provided for patients in the home blood pressure measurement arm. The final choice and dose of antihypertensive treatment(s) will be at the discretion of the treating clinicians. If no contra-indications, indapamide or other thiazide diuretic and/or angiotensin-converting enzyme (ACE) inhibitor (perindopril or other) will be encouraged as initial therapy, with long-acting calcium-channel antagonists (eg.amlodipine) encouraged as third-line therapy. Patients will have their home blood pressure monitoring diary reviewed by the study team. If SBP is out of the allocated target range, a prescription to titrate antihypertensive medication will be sent to the patient at least monthly.
Participants in the standard of care arm will receive antihypertensive therapy at the physician's discretion to the same treatment target of SBP \<130mmHg.
Difference in mean SBP
The difference in mean SBP between both groups, at 12 months (or last trial visit)
Time frame: 12 months (or last trial visit)
Proportions of patients assigned to each arm successfully reaching guideline-based target (SBP<130mmHg) at end of trial visit
Time frame: 12 months (or last trial visit)
Time in guideline-based target range
Proportion of SBP measures \<130 during trial participation
Time frame: 12 months (or last trial visit)
Time taken to reach target
Time taken to reach target SBP\<130mmHg
Time frame: 12 months (or last trial visit)
Difference in mean diastolic blood pressure (DBP) between groups
Time frame: 12 months (or last trial visit)
Change in SBP/DBP from baseline to end-of-trial
Time frame: 12 months (or last trial visit)
Time to first composite major adverse cardiovascular event (MACE), and to each component of the composite, stratified as fatal, non-fatal and total
MACE defined as all recurrent stroke, myocardial infarction, cardiac arrest
Time frame: 12 months (or last trial visit)
All-cause fatality
Time frame: 12 months (or last trial visit)
Comparison of disability in each intervention arm assessed by modified Rankin score
Shift analysis and proportion with no, mild, or moderate disability, Rankin score 0-3
Time frame: 12 months (or last trial visit)
Number of dose-titrations required
Time frame: 12 months (or last trial visit)
Time required per follow up visit
Time frame: 12 months (or last trial visit)
Number of patients lost to follow-up
Time frame: 12 months (or end of trial visit)
Number of serious adverse events
Difference in proportion of patients with serious adverse events
Time frame: 12 months (or last trial visit)
Number of pre-specified adverse events
Time frame: 12 months (or last trial visit)
Change in health related quality of life
Change in EQ5D-5L score (5 domains assessed with scores of 1-5 ranking the severity of impairment, with higher scores indicating poorer quality of life) at last follow-up compared with baseline
Time frame: 12 months (or last trial visit)
Change in cognition
Change in Montreal cognitive assessment score (range 0-30) at last follow-up compared with baseline score. A lower score indicates greater cognitive impairment.
Time frame: 12 months (or last trial visit)
Qualitative patient feedback obtained via workshops and questionnaires
Time frame: 12 months (or last trial visit)
Number of patients who do not complete the study due to tolerability or other issues
Patients who are not retained in the study will give an insight into anticipated retention in the Phase 3 trial and sample size considerations.
Time frame: 12 months (or end of trial visit)
Ability of sites to rapidly identify eligible patients from clinics and stroke units
The inclusion of prevalent cases already attending stroke clinics or discharged from stroke units within the last year is an important design feature, aimed to rapidly accrue patients into the trial and thus to maximise the duration of follow-up within the terms allowed by funders. This outcome will be judged on the basis of qualitative feedback from participating sites.
Time frame: 12 months (or end of trial visit)
Feasibility of home blood pressure (BP) measures and telemonitoring
This outcome will be judged on the basis of qualitative feedback from participants and the the proportions of participants adhering to the use of home blood pressure diaries.
Time frame: 12 months (or end of trial visit)
Compliance with telemonitoring and feasibility of remote (phone) visits
The feasibility of remote (phone) visits will be assessed by the proportion of patients adhering to participation in remote visit consultations
Time frame: 12 months (or end of trial visit)
Feasibility of remote BP titration
The feasibility of titration of BP based on prescriptions to pharmacies in response to BP telemonitoring
Time frame: 12 months (or end of trial visit)
Barriers to participation of women
Qualitative review to improve the design of a future Phase 3 trial with the aim of reducing barriers to women
Time frame: 12 months (or end of trial visit)
Plan to share: Undecided — The investigators are open to considering requests for collaborative projects.
Started May 2024 (actual). Primary completion is estimated for Dec 2025, 19 months after the start.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 19 months is below that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.